

Hyperparathyroidism in the hemodialysis population: A

American Journal of Kidney Diseases

29, 862-865

DOI: 10.1016/s0272-6386(97)90459-5

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prevention of renal osteodystrophy in peritoneal dialysis. <i>Kidney International</i> , 1998, 54, 2226-2233.	5.2	20
2	Predictors of Short-Term Changes in Serum Intact Parathyroid Hormone Levels in Hemodialysis Patients: Role of Phosphorus, Calcium, and Gender ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 3860-3866.	3.6	19
3	Calcification of the small bowel in renal hyperparathyroidism. <i>Journal of the Royal Society of Medicine</i> , 1998, 91, 430-431.	2.0	3
4	Divalent Ion Abnormalities and Hyperparathyroidism in the Etiology of Cardiovascular Disease of Patients with Chronic Renal Failure. <i>Seminars in Dialysis</i> , 1999, 12, 97-102.	1.3	4
5	A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 1999, 33, 694-701.	1.9	271
6	Vitamin D Therapy in Patients With Chronic Renal Disease: The Role of the Renal Dietitian. <i>Advances in Chronic Kidney Disease</i> , 2000, 7, 358-364.	2.1	2
7	Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. <i>Kidney International</i> , 2000, 57, 282-292.	5.2	92
8	Potential factors regulating serum parathyroid hormone in maintenance hemodialysis patients: 4-year retrospective study. <i>Clinical and Experimental Nephrology</i> , 2000, 4, 137-143.	1.6	0
9	High Prevalence of Hyperparathyroidism among Peritoneal Dialysis Patients: A Review of 176 Patients. <i>Peritoneal Dialysis International</i> , 2000, 20, 315-321.	2.3	24
10	Bone disease in patients with long-term renal transplantation and normal renal function. <i>American Journal of Kidney Diseases</i> , 2000, 36, 160-166.	1.9	119
11	Causes and Consequences of Adynamic Bone Disease. <i>Nephron</i> , 2001, 88, 97-106.	1.8	34
12	Sevelamer hydrochloride (Renagel [®]), a non α -calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1870-1878.	0.7	34
13	LONG-TERM INTRAVENOUS CALCITRIOL IN SECONDARY HYPERPARATHYROIDISM: THE ROLE OF TECHNETIUM-99M-MIBI SCINTIGRAPHY IN PREDICTING THE RESPONSE TO TREATMENT. <i>Renal Failure</i> , 2002, 24, 165-173.	2.1	7
14	Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1639-1642.	0.7	92
15	The Use of Sestamibi Imaging in Parathyroid Hyperplasia. <i>Clinical Nuclear Medicine</i> , 2002, 27, 865-867.	1.3	4
16	Parathyroid Hormone Suppression by Intravenous Calcitriol: Role of Phosphate, Calcium, Race and Diabetes. <i>American Journal of the Medical Sciences</i> , 2002, 323, 210-215.	1.1	6
17	Analysis of renal bone disease treatment in dialysis patients. <i>American Journal of Kidney Diseases</i> , 2002, 39, 1270-1277.	1.9	30
18	Update on vitamin D and its newer analogues: Actions and rationale for treatment in chronic renal failure. <i>Kidney International</i> , 2002, 62, 367-374.	5.2	56

#	ARTICLE	IF	CITATIONS
19	Evaluation of parathyroid hyperplasia by ultrasonographic examination in patients with end-stage renal failure before and at initiation of dialysis. <i>Nephrology</i> , 2003, 8, 116-120.	1.6	9
20	Secondary Hyperparathyroidism in Chronic Hemodialysis Patients: Prevalence and Race. <i>Renal Failure</i> , 2003, 25, 595-602.	2.1	45
21	The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 575-583.	6.1	245
22	Survival following parathyroidectomy among United States dialysis patients. <i>Kidney International</i> , 2004, 66, 2010-2016.	5.2	212
23	Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. <i>New England Journal of Medicine</i> , 2004, 350, 1516-1525.	27.0	1,023
24	Secondary hyperparathyroidism: Review of the disease and its treatment. <i>Clinical Therapeutics</i> , 2004, 26, 1976-1993.	2.5	75
25	Effectiveness of surgical parathyroidectomy for secondary hyperparathyroidism in renal dialysis patients in Qatar. <i>Transplantation Proceedings</i> , 2004, 36, 1815-1817.	0.6	11
26	Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2186-2193.	0.7	135
27	Control of Parathyroid Function in Patients with a Short History of Hemodialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2005, 9, 39-43.	0.9	3
28	Cinacalcet HCl, an Oral Calcimimetic Agent for the Treatment of Secondary Hyperparathyroidism in Hemodialysis and Peritoneal Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 800-807.	6.1	387
29	Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis. <i>Clinical Drug Investigation</i> , 2006, 26, 629-638.	2.2	14
30	Secondary Hyperparathyroidism in Chronic Kidney Disease: Focus on Clinical Consequences and Vitamin D Therapies. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1584-1593.	1.9	15
31	Influência do hiperparatireoidismo secundário grave no estado nutricional de pacientes com insuficiência renal crônica. <i>Revista De Nutricao</i> , 2006, 19, 111-118.	0.4	5
32	Relationship between Serum Magnesium, Parathyroid Hormone, and Vascular Calcification in Patients on Dialysis: A Literature Review. <i>Peritoneal Dialysis International</i> , 2006, 26, 366-373.	2.3	58
33	Body composition changes in haemodialysis patients with secondary hyperparathyroidism after parathyroidectomy measured by conventional and vector bioimpedance analysis. <i>British Journal of Nutrition</i> , 2006, 95, 353-357.	2.3	16
34	Inverse correlation between serum magnesium and parathyroid hormone in peritoneal dialysis patients: a contributing factor to adynamic bone disease?. <i>International Urology and Nephrology</i> , 2006, 38, 317-322.	1.4	37
35	Impact of Treatment with Calcimimetics on Hyperparathyroidism and Vascular Mineralization. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S281-S285.	6.1	12
36	Large Fluctuations in Parathyroid Hormone Concentrations After Autotransplantation of Parathyroid Tissue in the Forearm. <i>Clinical Chemistry</i> , 2007, 53, 534-535.	3.2	2

#	ARTICLE	IF	CITATIONS
37	Cinacalcet for the Treatment of Calciphylaxis. Archives of Dermatology, 2007, 143, 152-4.	1.4	55
38	Diabetic nephropathy in the elderly. Diabetes and Metabolism, 2007, 33, S40-S55.	2.9	48
39	Comparison of total parathyroidectomy without autotransplantation and without thymectomy versus total parathyroidectomy with autotransplantation and with thymectomy for secondary hyperparathyroidism: TOPAR PILOT-Trial. Trials, 2007, 8, 22.	1.6	45
41	Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease—mineral and bone disorder. International Urology and Nephrology, 2007, 39, 1251-1256.	1.4	15
42	Dose Determination of Cinacalcet Hydrochloride in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism. Therapeutic Apheresis and Dialysis, 2008, 12, 117-125.	0.9	29
43	Intravenous Alfacalcidol Once Weekly Suppresses Parathyroid Hormone in Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 2008, 12, 137-142.	0.9	4
44	Ultrasound Patterns of Parathyroid Glands in Chronic Hemodialysis Patients with Secondary Hyperparathyroidism. American Journal of Nephrology, 2008, 28, 589-597.	3.1	20
45	Cinacalcet Does Not Affect the Activity of Cytochrome P450 3A Enzymes, a Metabolic Pathway for Common Immunosuppressive Agents. Drugs in R and D, 2008, 9, 335-343.	2.2	8
46	Analisi costo-efficacia di cinacalcet pi ¹ terapia standard versus terapia standard nel trattamento dei pazienti in dialisi con iperparatiroidismo secondario. Pharmacoeconomics Italian Research Articles, 2008, 10, 13-22.	0.2	2
47	Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrology Dialysis Transplantation, 2008, 24, 982-989.	0.7	87
48	The OPTIMA Study. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 36-45.	4.5	202
49	The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS. CKJ: Clinical Kidney Journal, 2008, 1, i2-i6.	2.9	19
50	Vitamin C deficiency and secondary hyperparathyroidism in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2008, 23, 2058-2063.	0.7	44
51	Impact of Vitamin D Dose on Biochemical Parameters in Patients with Secondary Hyperparathyroidism Receiving Cinacalcet. Nephron Clinical Practice, 2009, 112, c41-c50.	2.3	7
52	Real-World Doxercalciferol Treatment in SHPT CKD Stage 3 and 4: An Analysis of Change in iPTH and Accordance to KDOQI Recommendations. American Journal of Nephrology, 2009, 29, 71-78.	3.1	2
53	Calcimimetics: A Review of the Recent Literature. Kidney, 2009, 18, 175-179.	0.0	2
54	Endoscopic Total Parathyroidectomy and Partial Parathyroid Tissue Autotransplantation for Patients with Secondary Hyperparathyroidism: A New Surgical Approach. World Journal of Surgery, 2009, 33, 1674-1679.	1.6	26
55	Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. Nephrology, 2009, 14, 488-492.	1.6	18

#	ARTICLE	IF	CITATIONS
56	Economic Analysis of Cinacalcet in Combination With Low-Dose Vitamin D Versus Flexible-Dose Vitamin D in Treating Secondary Hyperparathyroidism in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2010, 56, 1108-1116.	1.9	21
57	Treatment of secondary hyperparathyroidism in chronic kidney disease, and its effect on the QT interval. <i>Dialysis and Transplantation</i> , 2010, 39, 92-96.	0.2	0
58	Surgical or medical therapy for severe hyperparathyroidism or chronic kidney disease? An appraisal of current practice guidelines. <i>Acta Endocrinologica</i> , 2010, 6, 541-576.	0.3	2
59	Roles of Calcium-Sensing Receptor and Vitamin D Receptor in the Pathophysiology of Secondary Hyperparathyroidism. , 2010, 20, 141-150.		20
60	Intravenous Alfacalcidol Once Weekly Pulse Therapy for Secondary Hyperparathyroidism in Hemodialysis Patients. <i>Renal Failure</i> , 2011, 33, 329-333.	2.1	1
61	Cinacalcet. <i>Pharmacoeconomics</i> , 2011, 29, 807-821.	3.3	11
62	Presurgical Setting of Secondary Hyperparathyroidism Using High-Resolution Sonography and Color Doppler. <i>Ultraschall in Der Medizin</i> , 2011, 32, 74-82.	1.5	8
63	Efficacy and Tolerability of Intravenous Paricalcitol in Calcitriol-Resistant Hemodialysis Patients with Secondary Hyperparathyroidism: 12-Month Prospective Study. <i>Renal Failure</i> , 2012, 34, 297-303.	2.1	15
64	Parathyroid-gland ultrasonography in clinical and therapeutic evaluation of renal secondary hyperparathyroidism. <i>Radiologia Medica</i> , 2013, 118, 707-722.	7.7	9
65	Intravenous Alfacalcidol Once Versus Twice or Thrice Weekly in Hemodialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2013, 17, 30-34.	0.9	1
66	Short- and Long-Term Impact of Subtotal Parathyroidectomy on the Achievement of Bone and Mineral Parameters Recommended by Clinical Practice Guidelines in Dialysis Patients: A 12-Year Single-Center Experience. <i>Blood Purification</i> , 2013, 36, 116-121.	1.8	12
68	Calcium supplementation after parathyroidectomy in dialysis and renal transplant patients. <i>International Journal of Nephrology and Renovascular Disease</i> , 2014, 7, 183.	1.8	29
69	The relationship between secondary hyperparathyroidism and thyroid cancer in end stage renal disease: A population based cohort study. <i>European Journal of Internal Medicine</i> , 2014, 25, 276-280.	2.2	23
70	EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice. <i>Wiener Medizinische Wochenschrift</i> , 2015, 165, 410-418.	1.1	1
71	Severe Hyperkalaemia Complicating Parathyroidectomy in Patients with End-Stage Renal Disease. <i>Anaesthesia and Intensive Care</i> , 2017, 45, 365-368.	0.7	3
72	Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 901-909.	4.3	4
73	Effect of Cinacalcet on the Redox Status of Albumin in Secondary Hyperparathyroidism Patients Receiving Hemodialysis. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 1583-1590.	1.4	6
74	Total parathyroidectomy with autotransplantation in patients with renal hyperparathyroidism: indications and surgical approach. <i>Hormones</i> , 2006, 5, 270-275.	1.9	13

#	ARTICLE	IF	CITATIONS
75	Parathyroidectomy in Patients on Renal Replacement Therapy. Journal of the American Society of Nephrology: JASN, 2001, 12, 1242-1248.	6.1	128
76	The effects of sevelamer hydrochloride on metabolic acidosis in hemodialysis patients with citrate dialysate. Nihon Toseki Igakkai Zasshi, 2010, 43, 373-379.	0.1	2
77	Ultrasound in clinical setting of secondary hyperparathyroidism. Journal of Nephrology, 2013, 26, 848-855.	2.0	12
78	Epidemiology and mortality among dialysis patients with parathyroidectomy: Taiwan's National Cohort Study. Journal of Nephrology, 2013, 26, 1143-1150.	2.0	10
79	Nebenschilddr�sen. , 2000, , 203-329.		0
80	Chronische Niereninsuffizienz. , 2002, , 328-377.		0
81	Management of calcium by oral vitamin D analogs during calcimimetics therapy for secondary hyperparathyroidism. Nihon Toseki Igakkai Zasshi, 2009, 42, 857-863.	0.1	0
82	Chronische Niereninsuffizienz. , 2010, , 199-227.		0
83	Indikationen zur Nierenersatztherapie. , 2011, , 1-23.		0
84	Nebenschilddr�sen. , 2013, , 229-373.		0
85	Efficacy of Subtotal Parathyroidectomy in Secondary Renal Hyperparathyroidism: Long-Term Follow-Up Result. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2013, 56, 149.	0.2	0
86	Indikationen zur Nierenersatztherapie. , 2014, , 1-25.		0
87	Incidental Findings with Technetium-99m Methoxyisobutylisonitrile Imaging of Ectopic Parathyroid Hyperplasia in Patient with Intrathyroidal Parathyroid Hyperplasia. Soonchunhyang Medical Science, 2014, 20, 103-107.	0.0	0
88	Prevalence of Secondary Hyperparathyroidism among Hemodialysis Patients in Three Royal Medical Services Centers. Journal of the Royal Medical Services, 2015, 22, 12-17.	0.0	0
89	SURGICAL ANATOMY OF PARATHYROID GLANDS IN PATIENTS WITH SECONDARY HYPERPARATHYROIDISM. HERALD of North-Western State Medical University Named After I I Mechnikov, 2015, 7, 23-28.	0.2	1
90	Parathyroid ultrasonography and bone metabolic profile of patients on dialysis with hyperparathyroidism. World Journal of Nephrology, 2016, 5, 437.	2.0	2
91	Chronische Niereninsuffizienz. , 2007, , 197-225.		0
92	The value of clinical-ultrasonographic feature model to predict the severity of secondary hyperparathyroidism. Renal Failure, 2022, 44, 146-154.	2.1	1

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------